UY27770A1 - Imidazolinilmetil aralquilsulfonamidas - Google Patents

Imidazolinilmetil aralquilsulfonamidas

Info

Publication number
UY27770A1
UY27770A1 UY27770A UY27770A UY27770A1 UY 27770 A1 UY27770 A1 UY 27770A1 UY 27770 A UY27770 A UY 27770A UY 27770 A UY27770 A UY 27770A UY 27770 A1 UY27770 A1 UY 27770A1
Authority
UY
Uruguay
Prior art keywords
imidazolinilmetil
aralquilsulfonamidas
formula
methods
bicn
Prior art date
Application number
UY27770A
Other languages
English (en)
Inventor
Clara Jeou Jen Lin
Counde Oyang
Michael Patrick Dillon
Xiaoming Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of UY27770A1 publication Critical patent/UY27770A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compuestos de la fórmula: donde R1-R6 son aquellos bicn definidos aqui y los métodos para producirlo También se proporciona composiciones farmacéuticas que comprenden un compuesto de fórmula I y los métodos para su uso como agentes terapéuticos. i
UY27770A 2002-04-23 2003-04-22 Imidazolinilmetil aralquilsulfonamidas UY27770A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37470002P 2002-04-23 2002-04-23
US37877502P 2002-05-08 2002-05-08

Publications (1)

Publication Number Publication Date
UY27770A1 true UY27770A1 (es) 2003-10-31

Family

ID=29273005

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27770A UY27770A1 (es) 2002-04-23 2003-04-22 Imidazolinilmetil aralquilsulfonamidas

Country Status (22)

Country Link
US (2) US6756395B2 (es)
EP (1) EP1501817A1 (es)
JP (1) JP4362379B2 (es)
KR (1) KR100696561B1 (es)
CN (1) CN1296365C (es)
AR (1) AR039319A1 (es)
AU (1) AU2003227623B2 (es)
BR (1) BR0309668A (es)
CA (1) CA2483345C (es)
HR (1) HRP20040951A2 (es)
IL (1) IL164676A0 (es)
MX (1) MXPA04010315A (es)
MY (1) MY139228A (es)
NO (1) NO20044531L (es)
NZ (1) NZ535823A (es)
PA (1) PA8571401A1 (es)
PE (1) PE20040172A1 (es)
PL (1) PL373322A1 (es)
RU (1) RU2318814C2 (es)
TW (1) TW200306807A (es)
UY (1) UY27770A1 (es)
WO (1) WO2003091236A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003227623B2 (en) * 2002-04-23 2010-05-20 F. Hoffmann-La Roche Ag Imidazolinylmethyl aralkylsulfonamides
WO2005063678A1 (ja) * 2003-12-26 2005-07-14 Daiichi Pharmaceutical Co., Ltd フェニル酢酸誘導体の製造方法
WO2009100120A2 (en) 2008-02-04 2009-08-13 Neurogen Corporation Pyridinyl-substituted piperazinyl oxoethyl tetrahydropyrazolopyridines
MX2010007967A (es) * 2008-02-04 2010-08-09 Hoffmann La Roche N-[3-bromo-2-cloro-4-(4,5-dihidro-1h-imidazol-2-ilmetil)-fenil]-m etansulfoamida como agonista parcial alfa-1 a adrenergico para el tratamiento de la incontinencia.
CA2711724A1 (en) * 2008-02-04 2009-08-13 F. Hoffmann-La Roche Ag Novel imidazolinylmethyl aryl sulfonamides
JP2011511026A (ja) * 2008-02-04 2011-04-07 エフ．ホフマン−ラ ロシュ アーゲー 新規イミダゾリニルメチルアリールスルホンアミド
KR20100096261A (ko) * 2008-02-04 2010-09-01 에프. 호프만-라 로슈 아게 신규한 이미다졸리닐메틸 아릴 설폰아미드
JP4168086B1 (ja) * 2008-04-16 2008-10-22 国立大学法人福井大学 イミダゾリン誘導体
CN103664845B (zh) * 2013-12-27 2016-02-10 湖南欧亚生物有限公司 一种Plk激酶抑制剂药物中间体7-氨基-2,3-二氢苯并呋喃-4-甲酸的制备方法
CN103853429B (zh) * 2014-03-14 2018-01-23 联想(北京)有限公司 信息处理方法、信息处理装置及电子设备
CN105693524A (zh) * 2014-11-28 2016-06-22 浙江省化工研究院有限公司 一种硝基化合物的制备方法
EP4048263A4 (en) * 2019-10-25 2023-11-15 Curasen Therapeutics, Inc. METHOD FOR TREATING NEURONOLOGICAL DISORDERS USING PARTIAL ALPHA 1A-AR AGONISTS
EP4204404A4 (en) * 2020-08-27 2024-12-25 Curasen Therapeutics, Inc. Alpha1a-adrenergic receptor agonists and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3660423A (en) * 1970-02-13 1972-05-02 Dow Chemical Co 2-(substituted benzyl)methyl-2-imidazolines
AU3115471A (en) 1970-07-22 1973-01-18 Merck & Co Inc Chemical processes and products
CN1093535C (zh) * 1994-09-26 2002-10-30 盐野义制药株式会社 咪唑衍生物
SG72827A1 (en) * 1997-06-23 2000-05-23 Hoffmann La Roche Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives
TW405272B (en) 1997-06-25 2000-09-11 Sony Corp Method and apparatus for growth of a nitride III-V compound semiconductor
GB9910110D0 (en) * 1999-04-30 1999-06-30 Glaxo Group Ltd Chemical compounds
US6323231B1 (en) 2000-02-17 2001-11-27 Abbott Laboratories Use of α1A adrenoceptor agonists with α1B and α1D antagonism for the treatment of stress urinary incontinence
US6602897B2 (en) * 2000-10-14 2003-08-05 Boehringer Ingelheim Pharma Kg m-Amino-phenylimino-imidazolidine derivatives for treating urinary incontinence
US20020169193A1 (en) * 2001-02-10 2002-11-14 Pascale Pouzet Alkylphenyliminoimidazolidine derivatives for treating urinary incontinence
AU2003227623B2 (en) * 2002-04-23 2010-05-20 F. Hoffmann-La Roche Ag Imidazolinylmethyl aralkylsulfonamides

Also Published As

Publication number Publication date
PE20040172A1 (es) 2004-04-08
EP1501817A1 (en) 2005-02-02
WO2003091236A1 (en) 2003-11-06
PL373322A1 (en) 2005-08-22
JP4362379B2 (ja) 2009-11-11
RU2318814C2 (ru) 2008-03-10
US20040214875A1 (en) 2004-10-28
RU2004134326A (ru) 2006-01-27
TW200306807A (en) 2003-12-01
US7407980B2 (en) 2008-08-05
HRP20040951A2 (hr) 2006-06-30
NZ535823A (en) 2007-07-27
IL164676A0 (en) 2005-12-18
MY139228A (en) 2009-08-28
AU2003227623A1 (en) 2003-11-10
HK1080463A1 (en) 2006-04-28
KR20040102151A (ko) 2004-12-03
US20030229130A1 (en) 2003-12-11
KR100696561B1 (ko) 2007-03-19
US6756395B2 (en) 2004-06-29
CN1296365C (zh) 2007-01-24
NO20044531L (no) 2004-11-19
JP2005534628A (ja) 2005-11-17
AU2003227623B2 (en) 2010-05-20
BR0309668A (pt) 2005-03-01
CA2483345C (en) 2010-12-21
MXPA04010315A (es) 2005-06-08
CN1646516A (zh) 2005-07-27
CA2483345A1 (en) 2003-11-06
AR039319A1 (es) 2005-02-16
PA8571401A1 (es) 2004-02-07

Similar Documents

Publication Publication Date Title
UY28572A1 (es) Compuestos novedosos
UY27740A1 (es) Nuevos compuestos
AR028948A1 (es) Compuestos novedosos
PA8575401A1 (es) Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metrodos para su uso
ECSP055671A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesteresa
AR023727A1 (es) Compuestos empleados en el tratamiento de padecimientos inflamatorios
UY28144A1 (es) Agentes terapéuticos
UY31524A1 (es) Nuevos compuestos 010
PA8577001A1 (es) Benzoilureas heterociclicamente sustituidas, procedimiento para su preparacion y su uso como farmacos
SV1999000009A (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol ref. pg3388/sv
AR023574A1 (es) Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
CL2003002770A1 (es) Compuestos derivados de pirrol e imiddazol; composiciones farmaceuticas que los contienen; procedimiento de preparacion; y su uso en el tratamiento y/o prevencion de enfermedades que estan asociadas con la modulacion de los receptores a canabinoides
SV1999000016A (es) Derivados de 2-(purin-9-il-tetrahidrofuran-3,4-diol ref. pg3443/sv
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
CR8266A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
DOP2002000433A (es) 2-tio-3,5-diciano-4-fenil-6-aminopiridinas substituidas y su uso
UY27851A1 (es) Difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
SV2004001548A (es) Difenilazetidinonas sustituidas en grupo acido, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
UY27770A1 (es) Imidazolinilmetil aralquilsulfonamidas
PA8587501A1 (es) Benzoxazinonas sustituidas y usos de las mismas
PA8573501A1 (es) Derivados de benzoxazina y su empleo
UY28694A1 (es) Nuevos compuestos
PA8589801A1 (es) Aminoalcoxiindoles
PA8582201A1 (es) Indoles 2,7-sustituidos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150430